AKUR8
27.7.2021 09:02:06 CEST | Business Wire | Press release
Akur8 is pleased to announce its collaboration with Beesafe and Compensa, two entities of VIG Poland, to enhance their pricing process. With this new milestone, Akur8 continues to expand its European footprint, with 7 countries to date.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210727005010/en/
Specifically developed for insurers, Akur8’s solution boosts their pricing processes by automating risk and demand modeling, using transparent Artificial Intelligence proprietary technology. The core benefit for insurers is greater speed-to-accuracy, while maintaining full transparency and control on the models created.
VIG (Vienna Insurance Group) is one of the largest insurance groups in the world and one of the leading insurers in Austria and CEE countries. By collaborating with Akur8 for their motor insurance lines, Compensa will further accelerate their digital transformation, transforming the very core pricing process. Beesafe, a new, fully digital and direct entity created by VIG Poland, will be using Akur8 to launch their new product, leveraging the accelerated time-to-market benefits.
“We are very happy to support Beesafe and Compensa, part of VIG Poland, in taking a critical step towards insurance pricing sophistication and spurring digital transformation in their field. We are particularly humbled to accompany Beesafe in the launch of their fully digital journey, to help them bring their product to Polish consumers in a timely manner.”, says Samuel Falmagne, CEO at Akur8.
“It is great to be able to support VIG Poland in the launch of a new venture, whilst also reinforcing Akur8’s presence in Europe, Poland being our seventh European country of presence to date.”, says Brune de Linares, Chief of Sales at Akur8.
“Beesafe is a purely digital venture with a strong insurtech identity that we are extremely proud to be launching despite a very challenging context undermined by Covid. This is a strong testimony to the team’s commitment to continue to fuel digital transformation in our sector, sustained by collaborations with top-notch solutions that Akur8 epitomizes, for a highly strategic process that is pricing, all the more when launching a new product.”, says Rafał Mosionek, CEO at Beesafe and Executive Committee Member at Compensa, VIG Poland.
About Akur8
Akur8
is revolutionizing insurance pricing with transparent AI. Akur8 developed a unique AI-based insurance pricing solution that automates modeling for insurance companies while keeping full transparency and control on the models created, as required by regulators worldwide. Akur8 is the only solution on the market reconciling Machine Learning and Actuarial worlds.
About Beesafe
Beesafe
is a digital venture with a strong insurtech identity, benefiting from a quite unique positioning within the CEE area. The digital start-up was established by VIG, the leading insurance group in Austria, Central and Eastern Europe, to provide a dynamic distribution company with a unique customer offering, and potential for expansion into other countries where VIG operates.
About Compensa
Part of the Vienna Insurance Group, Compensa has been operating on the Polish market for many years, constantly developing its offer, service standards and sales network to exceed the expectations of the growing number of customers.
About VIG
Vienna Insurance Group (VIG)
is a leading specialist insurance company in Austria and Central and Eastern Europe. About 50 companies in 30 countries belong to it. It is a company with a long tradition, having strong brands and attaching great importance to customer proximity. VIG bases its activity on the foundation of almost 200 years of experience in the insurance industry. The Vienna Insurance Group, with around 25,000 employees, is the undisputed leader in the group's key markets and thus has an excellent market position enabling it to take advantage of long-term growth opportunities in a region with 180 million people.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210727005010/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom